Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HHS Drug Pricing Proposals: Some Things Are Off The Table

Executive Summary

The US Centers for Medicare and Medicaid Services is proposing an interesting package of innovative pricing policy changes, but some of the topics not included might be as important as the ideas that are.

You may also be interested in...

Could Drug Shortages Unlock Changes To Medicare Part B Payment?

The push to change the ‘ASP+6%’ reimbursement for physician-administered drugs in the US Medicare program is almost as old as the formula itself. Will the current drug shortage crisis provide a trigger to make changes at last?

Medicare Part D Redesign Will Sharpen Policy Focus On Protected Classes

Manufacturers worry that the redesign will prompt tighter controls in the protected classes, while some research indicates plans are already using all the tools at their disposal to manage some key classes, such as cancer drugs, suggesting they may need to be able to do more.

Medicare Will Test Payment Model For Accelerated Approvals To ‘Expedite’ Confirmatory Trials

The Center for Medicare and Medicaid Innovation also will develop demonstrations focused on payment arrangements for cell and gene therapy in Medicaid and promoting generic drugs in Medicare Part D.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts